Question special

In some other trials, treatment response has varied based on the patient's geographic location (for example...ticagrelor in PLATO, 2b/3a response in PURSUIT, beta-blocker response in MERIT-HF). Table 1 and the Supplemental appendix do not seem to identify any subgroup in whom the combined thromboprophylaxis group had a hypothesis-generating trend towards benefit. Recognizing the importance of overcoming publication bias and publishing trials that confirm the null hypothesis, do you think any further investigation is warranted regarding adjunctive intermittent pneumatic compression in addition to pharmacologic prophylaxis?